US EditionForbes Daily: Ozempic And Wegovy Maker Loses Big On Wall Street
DENMARK, JUL 29 – Novo Nordisk cut its 2025 sales growth forecast to 8-14%, down from 13-21%, citing increased competition in the U.S. market, triggering a 22% share price drop and major market value loss.
- Novo Nordisk, the Danish maker of Ozempic and Wegovy, posted its steepest single-day drop yesterday after slashing its 2025 sales and profit guidance.
- This decline followed a revised sales growth expectation of 8-14%, down from 13-21%, amid rising competition and disappointing trial results for some drugs.
- Eli Lilly's newer drugs, including Zepbound and Mounjaro, have surged past Wegovy in prescriptions, challenging Novo Nordisk's market position.
- Shares fell 23% yesterday, marking Novo's worst daily loss in 23 years, with shares down 58% over the last year; a new CEO was announced alongside this outlook cut.
- The share crash suggests investors may be reassessing weight loss drugs' impact, potentially benefiting alternative treatment providers like ResMed, which saw its shares rise.
Insights by Ground AI
Does this summary seem wrong?
Podcasts & Opinions
14 Articles
14 Articles
»This is a total reset of Novo Nordisk.« A total reset, concludes one of the largest private Danish investors, Henrik Blaagaard Hviid, who is a partner and portfolio manager at C Worldwide, the...
·Aarhus, Denmark
Read Full Article
New thunder on the Copenhagen Stock Exchange for the Danish giant. To contribute to investor uncertainty the exchange at the top and the entry of new competitors
·Italy
Read Full Article
Even the day after the price crash, shares of pharmaceutical manufacturer Novo Nordisk continue to decline. Analysts hastily revise their price targets downward, citing a competing product.
Coverage Details
Total News Sources14
Leaning Left1Leaning Right2Center2Last UpdatedBias Distribution40% Center, 40% Right
Bias Distribution
- 40% of the sources are Center, 40% of the sources lean Right
40% Right
L 20%
C 40%
R 40%
Factuality
To view factuality data please Upgrade to Premium
